A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients

Trial Profile

A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Anacetrapib (Primary) ; Atorvastatin
  • Indications Dyslipidaemias
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 01 Sep 2017 Results (n=12) of a substudy assessing mechanism by which CETP inhibition reduces Lp(a) published in the Arteriosclerosis Thrombosis and Vascular Biology
    • 16 Nov 2016 Results presented at the 89th Annual Scientific Sessions of the American Heart Association
    • 09 Sep 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top